Hydroxyprogesterone Caproate

CAS Number: 630-56-8

Molecular Formula: C27H40O4

About Hydroxyprogesterone Caproate

Hydroxyprogesterone caproate CAS 630-56-8 remains a cornerstone in the API intermediates market, primarily utilised as a long-acting synthetic progestin for treating advanced adenocarcinoma of the uterine corpus and managing hormonal imbalances like amenorrhea. 17-alpha-Hydroxyprogesterone hexanoate serves as a critica...

Hydroxyprogesterone Caproate Specifications

CAS Number

630-56-8

Molecular Formula

C27H40O4

Molecular Weight

428.60 g/mol

IUPAC Name

[(8R,9S,10R,13S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate

Canonical SMILES

CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O

InChI Key

DOMWKUIIPQCAJU-LJHIYBGHSA-N

PubChem CID

169870

CAS Number

630-56-8

Molecular Formula

C27H40O4

Molecular Weight

428.60 g/mol

IUPAC Name

[(8R,9S,10R,13S,14S,17R)-17-acetyl-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] hexanoate

Canonical SMILES

CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O

InChI Key

DOMWKUIIPQCAJU-LJHIYBGHSA-N

PubChem CID

169870

Molecular Weight

428.60 g/mol

Physical appearance

White to almost white powder to crystal

Progestin Hormone

A synthetic steroid hormone used as a long-acting injectable to manage various gynecological conditions including primary and secondary amenorrhea and abnormal uterine bleeding caused by hormonal imbalances

Antineoplastic Agent

A potent progestational ester utilized in the treatment of advanced adenocarcinoma of the uterine corpus, specifically Stage III or IV, to induce regressive changes in cancerous tissues

Diagnostic Aid

A pharmaceutical compound used as a medical test to evaluate natural endogenous estrogen production in non-pregnant women

Preterm Birth Risk Reducer

A medication historically indicated to reduce the risk of recurrent spontaneous preterm birth in women with a singleton pregnancy and a history of prior preterm delivery, though its FDA approval for this specific indication was withdrawn in 2023.